soul trial oral semaglutide cardiovascular outcomes nejm 2025 results 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM Oral Semaglutide and Cardiovascular Outcomes

This is creating demand for protein-led products such as protein yoghurts, shakes, snack bars and ready meals

Longitudinal data using DXA and sarcopenia-specific functional endpoints are warranted to elucidate the long-term musculoskeletal safety of these agents [105-108]

Individual preferences and insurance coverage play roles in final treatment choices, with a strong emphasis on the benefits over compounded alternatives in clinics that take insurance

Covering the drugs permanently would require a change in federal law or at least agreement among private health insurers to provide the medications in Part D plans

Frequently asked questions: You have options